We hypothesized that liraglutide attenuates DCM by modulating the ILK/PI3K/AKT signaling pathway and conducted this study to test our hypothesis in rats with streptozotocin (STZ)-induced T2DM. Here, ILK is linked to familial dilated cardiomyopathy.